论文部分内容阅读
目的探讨紫杉醇联合顺铂对晚期卵巢癌的短期疗效以及对免疫功能的影响。方法选取2010年1月至2014年1月间解放军第八十二医院收治的52例卵巢癌晚期患者,采用随机数字表法分为腹腔组(26例)和静脉组(26例)。腹腔组患者给予腹腔灌注顺铂+静脉滴注紫杉醇治疗,静脉组患者采用静脉滴注紫衫醇+顺铂治疗。治疗6周后,比较两组患者的疗效、化疗前后免疫功能指标的变化和不良反应等。结果腹腔组患者总有效率明显高于静脉组(P<0.05);化疗后两组患者血清中CD4~+CD25~+和CD4~+/CD8~+与化疗前比较,差异有统计学意义(P<0.05),且组间差异明显(P<0.05)。腹腔组患者腹水和糖蛋白抗原125(CA125)控制有效率均显著高于静脉组(P<0.05),两组患者不良反应总发生率间差异无统计学意义(P>0.05)。结论晚期卵巢癌采用紫杉醇联合顺铂化疗近期疗效显著,对免疫功能具有积极的影响,采用腹腔灌注治疗效果更好。
Objective To investigate the short-term effect of paclitaxel combined with cisplatin on advanced ovarian cancer and its effect on immune function. Methods 52 patients with advanced ovarian cancer who were admitted to the 82nd Hospital of PLA from January 2010 to January 2014 were randomly divided into abdominal cavity group (26 cases) and vein group (26 cases). Intraperitoneal patients were given intraperitoneal cisplatin + intravenous infusion of paclitaxel, intravenous infusion of patients with intravenous injection of paclitaxel + cisplatin treatment. After 6 weeks of treatment, the curative effect of two groups of patients, the change of immune function before and after chemotherapy and adverse reactions were compared. Results The total effective rate of the patients in the abdominal cavity group was significantly higher than that in the vein group (P <0.05). There was significant difference in the levels of CD4 ~ + CD25 ~ + and CD4 ~ + / CD8 ~ + in the two groups after chemotherapy P <0.05), and the difference between groups was significant (P <0.05). The control efficacy of ascites and glycoprotein antigen 125 (CA125) in patients with abdominal cavity was significantly higher than that of the vein (P <0.05). There was no significant difference between the two groups in overall incidence of adverse reactions (P> 0.05). Conclusion The treatment of advanced ovarian cancer with paclitaxel combined with cisplatin has a significant effect in the near future, which has a positive effect on immune function. The effect of peritoneal perfusion is better.